Results 81 to 90 of about 16,064,511 (322)

Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide

open access: yesCase Reports in Medicine, 2010
Proximal Crohn's disease, involving the esophagus, the stomach, the duodenum, and the proximal jejunum, is uncommon. Treatment for proximal Crohn's disease is based on data derived from case series than from controlled trials.
Petros Zezos   +4 more
doaj   +1 more source

Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2019
Significance The bacteria that live within the human gut play crucial roles in regulating our primary metabolism, protecting us from pathogens, and developing our immune system.
Matthew T. Henke   +5 more
semanticscholar   +1 more source

Crohn’s disease as an immunodeficiency [PDF]

open access: yesExpert Review of Clinical Immunology, 2010
The pathogenesis of Crohn's disease (CD) has widely been regarded as the consequence of a dysregulated T-cell-mediated response to intestinal microbes, and the majority of the worldwide research effort has focused on characterizing and treating the chronic inflammatory phase of the disease.
Arkwright, Peter; id_orcid 0000-0002-7411-5375   +5 more
openaire   +2 more sources

A Postbiotic‐Inducing Ganoderma applanatum Polysaccharide Repairs the Intestinal Barrier via a Phocaeicola vulgatus ‐ Tridecylic Acid Axis

open access: yesAdvanced Science, EarlyView.
This study identifies GAP2, a bioactive polysaccharide fraction derived from Ganoderma applanatum, as a postbiotic inducer that repairs intestinal barrier damage in a gut microbiota‐dependent manner. GAP2 enriches Phocaeicola vulgatus, which degrades GAP2 and promotes tridecylic acid production, triggering Rho/CDC42 signaling and tight‐junction ...
Chuan Zhang   +10 more
wiley   +1 more source

Crohn's disease [PDF]

open access: yes, 2013
Crohn's disease The Bachelor study summarizes the present knowledge of inflammatory diseases, which attack the digestive system. The Crohn's disease is classified as idiopathic or nonspecific intestine inflammations, since its cause is still not known ...
Štorkánová, Hana
core  

Oral Astilbin Nanogels Modulate Senescence‐Associated CD4+ T Cells and Promote Treg Induction in Aged Mice with Colitis

open access: yesAdvanced Science, EarlyView.
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao   +11 more
wiley   +1 more source

Ustekinumab-induced Henoch-Schönlein purpura in Crohn’s disease: a case report and literature review [PDF]

open access: yesIntestinal Research
Crohn’s disease is a chronic inflammatory disease of the digestive tract with extraintestinal manifestations, which include skin conditions, arthritis, ocular inflammation, and several autoimmune conditions. Dermatologic manifestations in Crohn’s disease
Merih Deniz Toruner   +4 more
doaj   +1 more source

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial

open access: yesGut, 2012
Objective The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease.
W. Hueber   +19 more
semanticscholar   +1 more source

Metastatic Crohn′s disease

open access: yesIndian Journal of Medical Research, 2015
Yes
Pérez-Belmonte, Luis-Miguel   +1 more
openaire   +3 more sources

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy